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ABSTRACT
Background Seasonal inﬂuenza A infection affects
a signiﬁcant cohort of the global population annually,
resulting in considerable morbidity and mortality.
Therapeutic strategies are of limited efﬁcacy, and during
a pandemic outbreak would only be available to
a minority of the global population. Over-the-counter
medicines are routinely taken by individuals suffering
from inﬂuenza, but few studies have been conducted to
determine their effectiveness in reducing pulmonary
immunopathology or the inﬂuence they exert upon the
generation of protective immunity.
Methods A mouse model of inﬂuenza infection was
utilised to assess the efﬁcacy of paracetamol
(acetaminophen) in reducing inﬂuenza-induced pathology
and to examine whether paracetamol affects generation
of protective immunity.
Results Administration (intraperitoneal) of paracetamol
signiﬁcantly decreased the inﬁltration of inﬂammatory cells
into the airway spaces, reduced pulmonary
immunopathology associated with acute infection and
improved the overall lung function of mice, without
adversely affecting the induction of virus-speciﬁc adaptive
responses. Mice treated with paracetamol exhibited an
ability to resist a second infection with heterologous virus
comparable with that of untreated mice.
Conclusions Our results demonstrate that paracetamol
dramatically reduces the morbidity associated with
inﬂuenza but does not compromise the development of
adaptive immune responses. Overall, these data support
the utility of paracetamol for reducing the clinical
symptoms associated with inﬂuenza virus infection.
INTRODUCTION
Inﬂuenza A viruses are responsible for seasonal
epidemics accounting for up to 500000 deaths per
annum worldwide; however, the propensity of these
viruses to acquire new genetic material from animal
reservoirs generates novel pandemic strains with
greater morbidity and mortality. The global impact
of inﬂuenza A has been ever-present throughout the
20th century with the Spanish (1918), Asian (1957)
and Hong Kong (1968) inﬂuenza pandemics. The
1918e1919 Spanish inﬂuenza pandemic was esti-
mated to have infected one-third of the world’s
population and accounted for 50e100 million
deaths.
1 In early 2009 attention was drawn to the
emergence of a new pandemic H1N1 inﬂuenza A
strain that quickly spread to all continents.
2 Thera-
peutic strategies for prevention and treatment of
inﬂuenza Aviruses remains a complex problem since
animal reservoirs and antigenic shift can create
potentially pandemic strains. This makes it difﬁcult
and costly to eliminate inﬂuenza A or create effec-
tive vaccines. Antiviral drugs are the ﬁrst line of
defence against new strains, but these are costly,
resistance may occur and availability is limited.
Many factors contribute to the pathophysiology
of inﬂuenza infection, including direct effects of
both the virus and host factors such as the
magnitude and type of immune response.
3e6 Over-
the-counter medicines that inhibit cyclo-oxygenase
(COX) such as aspirin, paracetamol (acetamino-
phen) and other non-steroidal anti-inﬂammatory
drugs (NSAIDs) are often taken to alleviate symp-
toms of inﬂuenza virus infection. Despite their
ubiquitous availability and use, the effects of this
group of drugs, including paracetamol, on inﬂuenza
infection have been poorly investigated. Although
widely used, the pharmacotherapeutic effects of
paracetamol remain controversial, with some
studies suggesting that the drug serves largely as an
analgesic while others report additional anti-
inﬂammatory effects (reviewed in Bertolini et al
7).
In support of an anti-inﬂammatory role, Hinz and
colleagues demonstrated that paracetamol inhibits
the activity of COX-2, an inducible enzyme that
generates prostaglandins (PGs), prostacyclin
and thromboxane.
8 The role of this enzyme in
inﬂuenza infection has been investigated further in
COX-2-deﬁcient mice which exhibit attenuated
pulmonary inﬂammation and delayed viral clear-
ance.
9 Administration of paracetamol might
therefore be expected to limit the severity of
inﬂuenza-induced lung pathology, but this could
adversely affect patients by impeding antiviral
responses.
10 Furthermore, perturbation of the
inﬂammatory response could impair the develop-
ment of protective immunity. Although inﬂuenza-
speciﬁc immune responses have not been assessed
in COX-2-deﬁcient mice, Prymula et al have
reported signiﬁcantly lower antibody responses to
some vaccines in infants receiving prophylactic
paracetamol compared with those that did not.
11
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Respiratory infectionIn view of the widespread availability of paracetamol and
NSAIDs amongst the general population, we sought to examine
the effects of paracetamol and a selective COX-2 inhibitor
(celecoxib) in a mouse model of inﬂuenza virus infection. We
hypothesised that administration of these drugs following
infection would diminish the immune response, delay virus
clearance and reduce immunopathology in target tissues. We
further hypothesised that the adaptive immune response would
be adversely affected, thereby compromising the establishment
of protective immunity. In this study, each hypothesis was
addressed by comparing innate and adaptive immune responses,
virus clearance, lung pathology and the ability to resist challenge
with heterologous inﬂuenza virus in both drug-treated and
untreated mice.
METHODS
Refer to the Supplementary information for a detailed descrip-
tion regarding the dose selection for celecoxib and paracetamol
used during this study, ﬂow cytometric analysis of pulmonary
cells and lung intracellular cytokine staining, determination of
serum alanine aminotransferase (ALT), quantiﬁcation of
pulmonary PGE2, in vivo lung function, in vitro virus titration
assays and the statistical tests used.
Murine inﬂuenza infection model
Female C57BL/6 mice were sourced from Charles River UK and
used at 8e10 weeks of age in experimental procedures in
compliance with UK Home Ofﬁce regulations.
Recombinant inﬂuenza A virus strains A-PR8-34 (PR8, H1N1)
and A/X31 (X31, H3N2) were obtained from the National
Institute for Medical Research (NIMR; London, UK). Mice were
infected intranasally with 50 plaque-forming units (pfu) of PR8
in 50 ml of sterile phosphate-buffered saline (PBS), under light
anaesthesia for primary inﬂuenza infection. Mice were injected
daily intraperitioneally with either 10 mg/kg of celecoxib or
125 mg/kg paracetamol for 10 days as described in the Supple-
mentary material. Memory recall responses to prior inﬂuenza
infection were examined by rechallenging previously infected
mice at 7e9 weeks after primary PR8 administration. Mice were
infected intranasally with 200 pfu of X31 in 50 ml of sterile PBS
under light anaesthesia. Body weight was recorded daily during
the course of infection until mice were sacriﬁced or until day 16
for memory studies.
Mice were sacriﬁced at days 4, 7 and 10 during primary
infection and day 4 after rechallenge, and bronchoalevolar
lavage (BAL) was performed. Following BAL, lungs were
isolated and kept on ice. A detailed description regarding BAL
and lung cell isolation is provided in the Supplemental
information.
Histopathology
At day 7 postinfection lungs were perfused with 5 ml of PBS and
ﬁxed with 10% neutral buffered formalin solution. Following
ﬁxation, lungs were embedded in parafﬁn and 5 mm sections
were cut. Sections were stained with H&E and scored blinded.
Lungs were scored using modiﬁed scoring criteria from Longhi
et al
12 and Ashcroft et al.
13 The degree of leucocyte inﬁltration of
the airway spaces and the formation of lymphoid aggregates
were independently scored on an increasing scale (0e3). These
were combined with the extent of perivascular lymphocytic
aggregation within each section (0e10), to give a score ranging
between 0 and 13. The mean score for each clinical parameter
was statistically compared between groups.
Determination of PR8-neutralising antibody titres
Serum was isolated from mice at 7e9 weeks postinfection with
PR8 and from naive uninfected mice. MadineDarby canine
kidney (MDCK) cells at 50% conﬂuence were plated into ﬂat-
bottomed 96-well plates and cultured for 48 h in the presence of
720 pfu of PR8 and serum at a 1:8 dilution. Cell viability was
calculated using alamar blue (Biosource International, Camarillo,
California, USA) according to the manufacturer’s guidelines.
The efﬁcacy of serum from inﬂuenza-primed mice to neutralise
PR8 was compared with the neutralising efﬁcacy of serum from
inﬂuenza-naive mice.
RESULTS
Celecoxib and paracetamol diminish inﬂuenza-associated
pulmonary PGE2 and reduce the extent of inﬂuenza-induced
airway inﬂammation
The anti-inﬂammatory effects of NSAIDs such as celecoxib are
attributed mainly to their ability to inhibit the activity of
COX-2, an enzyme which catalyses the biosynthesis of PGs
from arachidonic acid. COX-2 is upregulated during an inﬂam-
matory response, thereby increasing levels of PGs, most notably
PGE2, a metabolite known to modulate immune cell activity. To
determine whether PGE2 in the lungs of inﬂuenza-infected mice
is COX-2 derived, lipids from lungs of infected mice and infected
mice administered either celecoxib or paracetamol were analysed
using liquid chromatography/tandem mass spectometry. Our
data indicate that PGE2 is elevated in the lungs of inﬂuenza-
infected animals compared to uninfected controls (763 +/ 
75ng/mg vs 408 +/  128), and that this is inhibited by
administration of either celecoxib (3766122 ng/mg) or para-
cetamol (3686111 ng/mg) (data not shown). These observa-
tions indicate that elevated PGE2 following inﬂuenza infection is
COX-2 derived. A similar extent of PGE2 inhibition was observed
with celecoxib and paracetamol, in line with reports of their
comparable ability to inhibit PGE2 production in human blood.
8
Infection of mice with inﬂuenza virus typically results in
occlusion of the lung airway spaces by inﬂammatory cell inﬁl-
tration. To gain insight into the inﬂammatory response in the
airways, a quantitative analysis of the cellular composition of
BAL ﬂuid of infected mice was performed by ﬂow cytometry. As
expected, there was a highly signiﬁcant increase in the numbers
of cells recovered from BAL of infected mice compared with
uninfected animals (ﬁgure 1AeF). Paracetamol administration
signiﬁcantly reduced cell inﬁltration at days 4, 7 and 10 post-
infection. Detailed analysis showed signiﬁcantly fewer neutro-
phils, inﬂammatory monocytes, eosinophils and natural killer
(NK) cells in the BAL of paracetamol-treated animals compared
with untreated mice (ﬁgure 1CeF). A similar pattern was
observed in the celecoxib-treated group where a trend for fewer
cells was observed at each time point, although in this case
a statistically signiﬁcant difference was observed only at day 10.
Overall, these data imply a protective effect of paracetamol in
reducing the extent of inﬂuenza-induced immunopathology.
Airway function is improved in mice receiving celecoxib and
paracetamol
The observation that inﬂammation is reduced by paracetamol
administration is further supported by an analysis of airway
function in the same groups of mice. A group of inﬂuenza-
infected, untreated control animals and animals treated with
either paracetamol or celecoxib were subjected to airway func-
tion tests performed by whole-body plethysmography. This
technique measures changes in air pressure as a result of
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Figure 1 Effect of celecoxib or paracetamol upon inﬂuenza-induced airway inﬂammation and immunopathology. Bronchoalveolar lavage (BAL) ﬂuid
was aspirated at day 4, 7 or 10 postinfection and the airway-inﬁltrating cells were isolated. The total numbers of cells (A) and the numbers of alveolar
macrophages (B), neutrophils (C), inﬂammatory monocytes (D), eosinophils (E) and natural killer (NK) cells (F) at the selected time points were
determined by ﬂow cytometry. (G) At day 7 postinfection, airway hyper-responsiveness to inhaled methacholine (10 mg/ml for 5 min) was determined
by measuring changes in Penh (enhanced pause) 5 min after methacholine challenge, expressed as a percentage of the premethacholine baseline.
Changes in Penh were measured from naive mice, used as an uninfected control, and virus-infected mice treated or not with celecoxib or paracetamol.
Results are expressed as the mean6SEM for each group, n¼6 mice/group. The signiﬁcance of differences between drug-treated and untreated mice
was assessed using one-way analysis of variance with TukeyeKramers post hoc multicomparison test (AeF) and between infected and uninfected
mice using an unpaired t test (G), *p<0.05; **p<0.01; ***p<0.001.
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Respiratory infectioninspiration and expiration. In these experiments, enhanced pause
(Penh), a measurement of changes in expiratory effort, was used
as an indicator of airway obstruction. Speciﬁcally, control and
drug-treated animals infected 7 days previously with inﬂuenza
virus were challenged with aerosolised methacholine (10 mg/ml)
and Penh was measured. There was a signiﬁcant increase in the
peak Penh response in all infected mice compared with unin-
fected controls; however, this difference was less pronounced in
celecoxib- and particularly paracetamol-treated mice (ﬁgure 1G).
To assess if this improvement in lung function corresponded
to a reduction in inﬂuenza-induced pulmonary immunopa-
thology, lungs, recovered at day 7 postinfection, were assessed
histologically. Extensive leukocyte inﬁltration (ﬁgure 2A,C) and
perivascular aggregation (ﬁgure 2B,D) were observed in all
inﬂuenza-infected animals, when compared with uninfected
control animals. These observations, while not signiﬁcantly
different between drug-treated and untreated mice, when
combined with a notable improvement in lung function in
paracetamol-treated mice, imply a marked reduction in inﬂu-
enza-associated pathology during the acute stages of infection.
The effects of celecoxib or paracetamol on inﬂuenza-induced
liver dysfunction
Inﬂuenza infection of humans can be associated with an
increase in serum ALT levels and a transient and self-limiting
hepatitis.
14 Studies of mouse models of inﬂuenza infection
indicate that liver injury during inﬂu e n z ai n f e c t i o ni sn o t
attributable to inﬂuenza infection of the liver but rather
represents collateral damage caused by antigen-independent
sequestration of immune cells, most notably inﬂuenza-speciﬁc
CD8
+ Tcells in the liver. We sought to determine whether ALT
levels were increased in the serum of inﬂuenza-infected mice at
day 7 postinfection and whether this was reduced by admin-
istration of paracetamol or celecoxib. The results, shown in
ﬁgure 3A, indicate that both drugs virtually abolished inﬂu-
enza-induced increases in ALT levels. Weight loss is also
commonly used as an indicator of the severity of inﬂuenza-
induced pathology. However, we observed no change in weight
loss following inﬂuenza infection as a consequence of celecoxib
or paracetamol administration (ﬁgure 3B and Supplementary
ﬁgure 1).
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Figure 2 Histological analysis of pulmonary sections from treated and untreated mice postinfection with inﬂuenza virus. Lungs were harvested from
mice at day 7 postinfection and, following perfusion, were formalin ﬁxed, embedded in parafﬁn wax, sectioned and stained with H&E. (A and B)
Representative sections depicting pulmonary leukocytes from inﬂuenza-infected, treated and untreated mice were compared with uninfected mice
(original magniﬁcation310 (A)) Arrowheads highlight areas of lymphocytic perivascular aggregate (original magniﬁcation320 (B)). The mean
score6SEM for each group is given, n¼6 mice/group for the severity of inﬂuenza inﬁltrate (C) and degree of perivascular lymphoid aggregate (D). The
signiﬁcance of differences between inﬂuenza-infected mice and uninfected mice was determined using one-way analysis of variance with
TukeyeKramers multicomparison test, *p<0.05; **p<0.01.
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Respiratory infectionVirus clearance is unimpaired in celecoxib- or paracetamol-
treated mice
As paracetamol and, to a lesser extent, celecoxib reduces the
magnitude of the inﬂammatory response to inﬂuenza virus,
we hypothesised that viral clearance would be delayed in these
animals compared with non-treated controls. Viral titres in the
lungs of inﬂuenza-infected mice declined on days 7 and 10
compared with day 4 postinfection. Surprisingly we observed no
signiﬁcant differences in viral titres among the groups at any of
the time points analysed (ﬁgure 4).
Protective immunity is not impaired in mice treated with
paracetamol or celecoxib during primary infection with
inﬂuenza virus
A reduction in inﬂuenza-induced innate immune responses as
a consequence of celecoxib or paracetamol treatment could alter
the magnitude of the virus-speciﬁc adaptive immunity. To
investigate this, interferon g (IFNg)- and tumour necrosis factor
a (TNFa)-producing CD4
+ and CD8
+ Tcells in the lungs were
measured at day 10 postinfection. The number of cytokine-
producing cells was, as expected, elevated as a result of the
infection, but there was no statistically signiﬁcant difference
between inﬂuenza-infected groups treated or not with drugs
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Figure 3 Effect of cyclo-oxygenase 2 (COX-2) inhibition upon clinical
parameters of primary inﬂuenza infection. (A) Serum collected from mice
at day 7 postinfection was used to determine circulating alanine
aminotransferase (ALT) levels during acute inﬂuenza infection. Results
are expressed as the mean6SEM, n¼6e16 mice/group. (B) Post-PR8
infection mice were weighed daily for 16 days, and changes in body
weight were expressed as a percentage of their starting weight. Each
data point represents the mean6SEM, n¼6 mice/group. The
signiﬁcance of differences between drug-treated and untreated mice
was assessed using one-way analysis of variance with post hoc
TukeyeKramer multiple mean comparison,*p<0.05; **p<0.01;
***p<0.001.
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Figure 4 Pulmonary viral load during acute inﬂuenza infection. At days
4, 7 and 10 postinfection mice were sacriﬁced and the lungs were
extracted and homogenised. Pulmonary viral titres were determined
using the previously described MDCK (MadineDarby canine kidney)
virus quantitation assay; results are given as the mean for each
group6SEM, n¼4e9 mice/group.
Figure 5 Adaptive immune responses
following acute inﬂuenza infection and
inhibition of cyclo-oxygenase 2 (COX-2).
(AeC) Lungs were harvested at day 10
postinfection and a single cellular
suspension was achieved following
collagenase digestion. Lung cells were
stimulated for 5 h in vitro with PMA
(phorbol 12-myristate 13-acetate) and
ionomycin; the numbers of CD4
+ (A)
and CD8
+ T cells (B) secreting tumour
necrosis factor a (TNFa) and interferon
g (IFNg) were determined by ﬂow
cytometry. (C) Alternatively, lung cells
were not stimulated and the percentage
of CD8
+ inﬂuenza-speciﬁc tetramer
+
cells was determined by ﬂow
cytometry. (D) Serum from both treated
and untreated mice was isolated at
7e9 weeks postinfection with
50 plaque-forming units of PR8. The
relative neutralising antibody activity of
each group of mice was determined
using the neutralising antibody titre
assay described in the Methods section.
Each data point given is the
mean6SEM, n¼3e6 mice/group.
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Respiratory infection(ﬁgures 5A,B and Supplementary ﬁgure 2). As an additional
measure of the inﬂuenza-speciﬁc CD8
+ Tcell response, nucleo-
protein-64 (NP-64) tetramers were used. The results shown in
ﬁgure 5C indicate that the administration of either celecoxib
or paracetamol did not signiﬁcantly alter the induction of
virus-speciﬁc CD8
+ Tcell responses.
Finally, the virus-neutralising capacity of serum recovered
from treated and untreated mice was assessed and, again, no
signiﬁcant difference was observed between mice in the different
treatment groups (ﬁgure 5D). As expected, the neutralising
ability of serum from all inﬂuenza-infected memory mice was
signiﬁcantly greater than that from naive uninfected mice.
Overall these data indicate that while administration of para-
cetamol or celecoxib reduces the inﬂammatory response induced
by inﬂuenza virus infection, there is no effect on the adaptive
immune response.
As the adaptive immune response was unimpaired in mice
treated with COX-2 inhibitors, we considered it likely that
there would be no loss of protective immunity in these mice.
To determine this, mice infected with the PR8 virus at least
8 weeks previously were rechallenged with the heterologous
inﬂuenza virus, X-31, enabling assessment of hetero-subtypic
immunity. In this case, T cells would mediate protective
immunity given that neutralising antibodies raised following
PR8 infection do not cross-neutralise the X-31 virus. As
expected, prior infection with the PR8 virus did confer some
protection against infection with X-31 as these animals
displayed signiﬁcantly less weight loss than animals that had
not experienced a prior exposure to inﬂuenza (ﬁgure 6A). In
agreement with this, viral titres were signiﬁcantly reduced in
PR8-immune mice, including those treated with either para-
cetamol or celecoxib during the primary infection, compared
with mice exposed to inﬂuenza virus for the ﬁrst time (ﬁgure
6B). These ﬁndings indicate that administration of paracetamol
or celecoxib does not compromise the development of protective
Tcell-mediated immunity.
DISCUSSION
The current study set out to examine the impact of paracetamol
on the course of inﬂuenza virus infection, focusing on viral
clearance, the generation of innate and adaptive immune
responses and the establishment of protective immunity. The
data clearly demonstrate that in the context of the inﬂuenza-
infected lung, paracetamol reduces pulmonary PGE2 and
inﬂammation without compromising virus clearance or the
generation of protective immunity.
During the early stages of virus infection (days 4e10) we
found that paracetamol reduced the magnitude of inﬁltration of
innate cells into the lungs. A similar trend, although to a lesser
extent, was observed in those treated with the selective COX-2
inhibitor celecoxib. These results are similar to ﬁndings using
COX-2-deﬁcient mice.
9 The effect of inﬂuenza infection was less
severe in COX-2-deﬁcient animals, as demonstrated by decreased
mortality and a blunted inﬂammatory response compared with
wild-type animals. However, elevated virus titres were observed
in the animals, indicating, in contrast to our own ﬁndings, that
the abrogated inﬂammatory response was associated with
poorer control of virus. The more pronounced effects observed in
COX-2-deﬁcient animals compared with those treated with
COX-2 inhibitors may reﬂect developmental differences in
the genetically modiﬁed animals affecting the function of the
immune system and/or the difference between a complete
(COX-2
 /  animals) and transient (drug administration) block
of COX activity.
Inﬂuenza infection caused airway hyper-responsiveness to the
inhaled spasmogen, methacholine, in agreement with previous
reports,
15 which was reduced following treatment with para-
cetamol or celecoxib. Thus, paracetamol appears to play
a protective role, reducing lung pathology and helping to
preserve lung function. Patients infected with seasonal inﬂuenza
A, who subsequently develop severe respiratory failure, are
characterised by a profound early inﬂammatory inﬁltrate and
cytokine release. The same was true for the 2009 novel H1N1
inﬂuenza A pandemic where severe lung injury occurred in
young adults in whom it was frequently difﬁcult to maintain
oxygenation. Autopsies on patients succumbing to this new
inﬂuenza strain showed pulmonary pathology similar to
previous pandemics, with profound cellular inﬁltrates and
diffuse alveolar damage.
16e18 Thus paracetamol may, through
inhibition of COX-2, afford protection for patients infected with
inﬂuenza and complicated by respiratory failure through atten-
uation of the proinﬂammatory response. The importance of the
COX-2 pathway in severe respiratory failure is further
substantiated by experiments using avian H5N1 inﬂuenza A
virus.
19 Avian H5N1 infection has a case death approaching 30%
but is not transmissible between humans; it is characterised by
severe respiratory failure with inﬂammatory inﬁltrates within
the lung and high levels of inﬂammatory cytokines such as
TNFa and IFNg.
20 21 Compared with seasonal H1N1 inﬂuenza
Avirus, avian H5N1 differentially upregulates COX-2 in primary
human macrophages in vitro and epithelial cells in vivo, the
increased expression resulting from autocrine or paracrine
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Figure 6 Protective immune responses to secondary inﬂuenza
infection. (A and B) At 7e9 weeks postinfection mice were rechallenged
with 200 plaque-forning units (pfu) of X31. (A) Mice were weighed prior
to secondary infection to provide a baseline 100% starting weight and for
4 days thereafter. Each data point represents the mean6SEM for each
group, n¼3e6 mice/group. (B) At day 4 after secondary infection, mice
were sacriﬁced and the lungs were harvested following perfusion with
phosphate-buffered saline. Lungs were homogenised and the viral load
was determined using the previously described MDCK (MadineDarby
canine kidney) plaque assay. Plots represent the mean of each
group6SEM, n¼6 mice/group, 3 mice/group for PR8-naive mice. The
signiﬁcance of differences between previously PR8-infected mice and
PR8-naive mice was evaluated using one-way analysis of variance with
TukeyeKramer multiple comparison post hoc test, ***p<0.001.
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Respiratory infectionmediators rather than direct effects of the virus.
19 Expression of
inﬂammatory cytokines is driven by COX-2 upregulation and
can be effectively inhibited with selective COX-2 inhibitors.
19 In
another murine model of avian H5N1 infection, addition of the
selective COX-2 inhibitor celecoxib to the neuraminidase
inhibitor zanamivir reduced lung inﬂammation and virus titres
and increased survival from 13.3% to 53.3% and mean survival
time from 8.4 to 13.3 days compared with zanamivir alone.
22 It
is clear from this study and our own that attenuating the
inﬂammatory response to inﬂuenza does not compromise virus
clearance. Indeed, overall we observed a trend for better virus
control in the treated animals.
Overall these data support a protective role for paracetamol
during the acute stage of infection with inﬂuenza virus. We
considered it important that the impact of paracetamol
administration at this time on the generation of inﬂuenza-
speciﬁc responses was also assessed. As the innate immune
response inﬂuences the development of the adaptive response,
attenuation of this response through the effects of paracetamol
could suppress the virus-speciﬁc immune response. In addition,
PGE2 has been shown in vivo to promote T helper 1 (Th1) cell
differentiation, thus inhibition of PGE2 could directly down-
modulate development of inﬂuenza-speciﬁc Tcell and antibody
responses.
23 In support of this, a recent report detailing antibody
responses in 226 infants receiving vaccines demonstrated
signiﬁcantly lower antibody titres in those receiving prophy-
lactic paracetamol.
11 Our data clearly show, however, no
signiﬁcant differences in the inﬂuenza-speciﬁc immune response
in drug-treated and untreated animals. Importantly, the ability
of drug-treated mice to resist rechallenge with a heterotypic
inﬂuenza virus was unimpaired.
The current study demonstrates that both paracetamol and
celecoxib, which inhibit COX-2, attenuate pulmonary inﬂamma-
tion without impeding virus clearance or the development of
speciﬁc immunity in mice. While the doses of paracetamol used are
different for mice and humans, as described in the Supplementary
material, the implications of the study are clear. Over-the-counter
medicines such as paracetamol, which inhibit COX-2, are cheap,
widely available and target the host response rather than the virus,
and therefore offer an attractive therapeutic option.
24 However,
with the information currently available on the effects of para-
cetamol upon inﬂuenza infection, it is possible that its impact may
differ in mice and humans. It is important that these observations,
generated using a mouse model, are validated with respect to the
action of paracetamol and its impact on the immune system in
clinical studies of human inﬂuenza virus infection.
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